Logo

early detection

CorePath Laboratories, Cizzle Biotechnology Partner on Lung Cancer Blood Test 

CorePath will develop and offer UK-based Cizzle's test in the US, with royalty agreements on all product and services offerings related to the test. 

Mainz Biomed, Dante Labs Partner to Commercialize ColoAlert in Europe, UAE

Dante labs will market the test in Italy and the UAE, with Mainz initially processing samples in its lab and Dante later adopting IVD kits for in-house use.

Delfi Diagnostics, Memorial Sloan Kettering Partner to Advance Cancer Screening Technology

The partners' first project is an expansion of Delfi's previously announced prospective study of its blood-based screening assay in patients with a high risk of lung cancer.

Intermountain Healthcare Rolling Out Galleri Multi-Cancer Early Detection Test in Pilot Program
Premium

The test is first available to employees over age 50 covered under Intermountain's SelectHealth, but the health system has a bigger five-year plan.

Guardant Health Confident in New CRC Screening Blood Test Despite Competitor Skepticism
Premium

Having officially launched its Shield colorectal cancer screening assay as an LDT, Guardant stands to benefit from a head start in clinical establishment.

Apr 29, 2022

Exai Bio Commercializing Noncoding RNA Method for Liquid Biopsy Applications
Premium

Apr 28, 2022

As Competing Blood-Based Cancer Screening Tests Loom, Exact Sciences Stresses Cologuard Advantage
Premium

Apr 21, 2022

Consensus Builds for Real-World Evidence to Support Multi-Cancer Screening Tests
Premium

Apr 13, 2022

Guardant Health, Exact Sciences Make Progress on Multi-Cancer Detection Tests
Premium

Mar 31, 2022

New Esophageal Cancer Tests on Horizon as Hopkins Spinout Capsulomics Preps Clinical Launch
Premium

Mar 30, 2022

Genetron Health Adds New Assays to Pipeline While Anticipating MRD Launch, Liver Cancer Kit Trials
Premium

Mar 23, 2022

Burning Rock Adds Validation Data as it Begins MRD and Early Detection Commercialization
Premium

Mar 22, 2022

Burning Rock Q4 Revenues up 12 Percent

Feb 15, 2022

Point32Health to Offer Grail Cancer Early Detection Test Under Pilot Program

Feb 2, 2022

President Biden Jumpstarts Cancer Moonshot Initiative With Goal of Halving Death Rate

Jan 19, 2022

Mainz Biomed Taps DCN Dx to Aid European Study of Enhanced ColoAlert Assay

Jan 11, 2022

Freenome Nets $290M Investment From Roche

Jan 7, 2022

Banner Year for Blood-Based Cancer Screening in 2021, but Reimbursement and Utility Hurdles Loom
Premium

Nov 17, 2021

Burning Rock Details Launch Plans for Three New Oncology Assays in 2022
Premium

Nov 16, 2021

BioMark Diagnostics Nabs Canadian Funding for Lung Cancer Liquid Biopsy

Nov 5, 2021

Pancreatic Cancer Application Provides First Toehold for Biological Dynamics in Clinical Testing
Premium

Oct 28, 2021

Veracyte Builds Data for Lung Cancer Swab Test, Begins Limited Launch
Premium

Sep 1, 2021

Burning Rock Details Plans for Cancer Monitoring Assay, Adds New Data Supporting Early Detection
Premium

Aug 27, 2021

Delfi Diagnostics Tags Lung Cancer as First Target for Fragmentation-Based Liquid Biopsy Tech
Premium

Aug 18, 2021

Illumina Acquires Grail Despite Ongoing Regulatory Scrutiny